Alanna Nattis, DO
Ophthalmology · Westbury, NYNPI 1558700542
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $32,875 of the $43,084 with a category attached, or 76.3%. 25 manufacturers reported payments, led by Alcon at 39.9% of the total. Reporting peaked in 2020 at $21,389 and has fallen 96.5% since, to $758 in 2025. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 186 payments — averaging $231.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$17K
- Novartis$11K
- Alcon Research LLC$5K
- Sight Sciences, Inc.$3K
- Tarsus Pharmaceuticals, Inc.$3K
- Glaukos Corporation$1K
- plus $4K from 19 others
Across 87 payments — averaging $6369.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$280K
- Ocular Therapeutix, Inc.$131K
- Glaukos Corporation$71K
- Topcon Healthcare, Inc.$47K
- Bausch Health US, LLC$23K
- Tarsus Pharmaceuticals, Inc.$2K
What the payments were for
- Consulting fees$32,87576%
- Speaking & faculty fees$3,1007%
- Travel & lodging$1,7154%
- Food & beverage$5,39413%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 32 | $17,189 |
| Novartis | 19 | $10,641 |
| Alcon Research LLC | 2 | $4,550 |
| Sight Sciences, Inc. | 9 | $3,106 |
| Tarsus Pharmaceuticals, Inc. | 1 | $2,625 |
| Glaukos Corporation | 8 | $1,353 |
| AbbVie(2 entities) | 34 | $745 |
| Biotissue Holdings Inc. | 13 | $412 |
| Eyevance Pharmaceuticals LLC | 5 | $389 |
| Harrow Eye, LLC | 7 | $307 |
| Dompe US, Inc. | 8 | $264 |
| Oyster Point Pharma, Inc. | 10 | $258 |
| Ocular Therapeutix, Inc. | 6 | $231 |
| Bausch & Lomb Americas Inc. | 5 | $216 |
| Kala Pharmaceuticals, Inc. | 4 | $182 |
| Carl Zeiss Meditec, Inc. | 1 | $142 |
| Shire North American Group Inc | 4 | $96 |
| Mallinckrodt Hospital Products Inc. | 5 | $93 |
| Sun Pharmaceutical Industries Inc. | 4 | $70 |
| Apellis Pharmaceuticals, Inc. | 2 | $63 |
| Amgen | 2 | $52 |
| Aerie Pharmaceuticals, Inc. | 1 | $35 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $33 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $20 |
| Topcon Healthcare, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$10,459
- AcrySof IQ PanOptix$8,750
- AcrySof IQ VIVITY IOL$6,650
- PanOptix$4,404
- ORA$2,800
- TearCare$1,500
- TearCare SmartLid$1,500
- TEARCARE(TM) (2.2) SYSTEM KIT$1,500
- AcrySof$700
- DEXTENZA$401
- Zerviate$160
- Clareon PanOptix Pro$150
- Flarex$149
- MIEBO$148
- VERACITY SURGICAL$142
- ReSure Sealant$134
- INVELTYS$125
- IACCESS$114
- iStent inject W$114
- Oxervate$103
How this compares
$43,084 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 59 | $78,736 |
| XiidraLifitegrast | 36 | $47,456 |
| XdemvyLotilaner | 14 | $24,880 |
| LumiganBimatoprost | 32 | $16,422 |
| MieboPerfluorohexyloctane/Pf | 16 | $12,106 |
| Cyclosporine | 25 | $7,383 |
| Prednisolone Acetate | 268 | $7,332 |
| Brimonidine Tartrate | 47 | $4,557 |
| Ketorolac Tromethamine | 213 | $3,793 |
| Travoprost | 12 | $2,891 |
| Ofloxacin | 250 | $2,428 |
| Latanoprost | 224 | $2,245 |
| Timolol Maleate | 56 | $1,945 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 19 | $1,751 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 64 | $1,023 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $745 | $95,15991 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $216 | $59,56252 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $2,625 | $24,88014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Westbury
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Jonathan JonischGreat Neck$726K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.